From the first comprehensive mapping of the TP53 mutation rate in a homogeneous group of high-grade serous ovarian cancer patients, the overall TP53 dysfunction rate approached 100% of 123 patients. Here, TP53 is linked to ovarian serous adenocarcinoma.